GETI.B

184.25

+1.04%↑

EKTA.B

56.5

+1.25%↑

AMBEA

127.8

-2.29%↓

ARJOB

24.92

-0.24%↓

MSON.B

11.85

+3.49%↑

GETI.B

184.25

+1.04%↑

EKTA.B

56.5

+1.25%↑

AMBEA

127.8

-2.29%↓

ARJOB

24.92

-0.24%↓

MSON.B

11.85

+3.49%↑

GETI.B

184.25

+1.04%↑

EKTA.B

56.5

+1.25%↑

AMBEA

127.8

-2.29%↓

ARJOB

24.92

-0.24%↓

MSON.B

11.85

+3.49%↑

GETI.B

184.25

+1.04%↑

EKTA.B

56.5

+1.25%↑

AMBEA

127.8

-2.29%↓

ARJOB

24.92

-0.24%↓

MSON.B

11.85

+3.49%↑

GETI.B

184.25

+1.04%↑

EKTA.B

56.5

+1.25%↑

AMBEA

127.8

-2.29%↓

ARJOB

24.92

-0.24%↓

MSON.B

11.85

+3.49%↑

Home・Aandelen Lijst・Attendo AB

Attendo AB

Gesloten

98.8 -0.4

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

97.4

Max

99.5

Belangrijke statistieken
By Trading Economics
Inkomsten	161M 494M
Verkoop	27M 4.8B
K/W Sectorgemiddelde	18.672 57.833
EPS	1.65
Dividendrendement	1.8
Winstmarge	10.3
Werknemers	33,000
EBITDA	-79M 1.1B

Dividenden
By Dow Jones
Dividendrendement Sectorgemiddelde	1.80% 2.47%

Marktinformatie
By TradingEconomics
Marktkapitalisatie	11M 15B
Vorige openingsprijs	99.2
Vorige sluitingsprijs	98.8

Attendo AB Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 mrt 2026, 23:47 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mrt 2026, 22:55 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mrt 2026, 21:51 UTC

Acquisities, Fusies, Overnames

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mrt 2026, 23:59 UTC

Marktinformatie

Global Equities Roundup: Market Talk

23 mrt 2026, 23:59 UTC

Marktinformatie

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mrt 2026, 23:50 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mrt 2026, 23:37 UTC

Marktinformatie

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mrt 2026, 22:42 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Global Equities Roundup: Market Talk

23 mrt 2026, 22:42 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mrt 2026, 22:40 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mrt 2026, 22:23 UTC

Marktinformatie

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mrt 2026, 22:22 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mrt 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mrt 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mrt 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mrt 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mrt 2026, 22:19 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mrt 2026, 22:19 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mrt 2026, 22:18 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mrt 2026, 22:15 UTC

Acquisities, Fusies, Overnames

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mrt 2026, 22:08 UTC

Marktinformatie

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mrt 2026, 21:42 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

23 mrt 2026, 21:42 UTC

Marktinformatie

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mrt 2026, 21:10 UTC

Belangrijke Nieuwsgebeurtenissen

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mrt 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

23 mrt 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

23 mrt 2026, 20:50 UTC

Marktinformatie

Winsten

Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Attendo AB Prognose

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Attendo AB

Attendo AB (publ) provides health and care services in Scandinavia and Finland. The company offers nursing homes for people with dementia or physical care requirements; home care services, including care, meals, cleaning, laundry, evening and night, and home health care services for older people; homes for people of various ages with a range of disabilities or care needs; respite and companion services, as well as short term accommodation; homes and other care services for people with neuropsychiatric and psychosocial impairments; and social-worker supported foster care, crisis and emergency accommodation, HVB-homes, addiction care, and various forms of supportive housing services. Attendo AB (publ) was founded in 1985 and is headquartered in Danderyd, Sweden.